Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126366001 | 12636600 | 1 | I | 20160801 | 20160809 | 20160809 | EXP | US-ASTRAZENECA-2016SE83709 | ASTRAZENECA | 0.00 | F | Y | 0.00000 | 20160809 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126366001 | 12636600 | 1 | PS | ANASTRAZOLE | ANASTROZOLE | 1 | Oral | U | 20541 | TABLET | |||||||||
| 126366001 | 12636600 | 2 | SS | FASLODEX | FULVESTRANT | 1 | Intramuscular | U | 0 | INJECTION | |||||||||
| 126366001 | 12636600 | 3 | SS | FASLODEX | FULVESTRANT | 1 | Intramuscular | U | 0 | INJECTION | |||||||||
| 126366001 | 12636600 | 4 | SS | TAMOXIFEN | TAMOXIFEN | 1 | Oral | U | 0 | TABLET | |||||||||
| 126366001 | 12636600 | 5 | SS | IBRANCE | PALBOCICLIB | 1 | Oral | U | U | 0 | CAPSULE |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126366001 | 12636600 | 5 | Breast cancer female |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126366001 | 12636600 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126366001 | 12636600 | Breast cancer | |
| 126366001 | 12636600 | Disease progression |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |